SSS Sunvest Minerals Corp

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS)(OTCQX:SCTPF), an immuno-oncology
company developing cancer stem cell-related therapeutics, today announced that
Mr. Luke Beshar and Dr. Thomas Reynolds have been appointed to the Company's
Board of Directors.


Luke Beshar is Executive Vice President and Chief Financial Officer of NPS
Pharmaceuticals. He joined the company in 2007 and has been responsible for
financial management, investor relations, information technology, technical
operations, supply- chain management, facilities, project management, contracts
& outsourcing, and alliance management. Mr. Beshar has utilized his 30 years of
experience and strategic and financial expertise to help transform NPS into a
global biopharmaceutical company that is bringing innovative therapies to
patients with rare diseases around the world. Under his financial leadership,
NPS secured approximately $400M of capital and its market capitalization
increased from $180 million to more than $3 billion. Prior to joining NPS, Mr.
Beshar served as Executive Vice President and Chief Financial Officer of Cambrex
Corporation, a global life sciences company. At Cambrex, his accomplishments
included raising approximately $600 million of new capital, building a high
performance global finance team, and leading a process of evaluating strategic
alternatives, which resulted in the sale of non-strategic operations for $460
million and an $11 per share special dividend to shareholders. Mr. Beshar began
his career with Arthur Andersen & Co. and is a certified public accountant. He
obtained his bachelor's degree in Accounting and Finance from Michigan State
University and is a graduate of The Executive Program at the Darden Graduate
School of Business at the University of Virginia.


Dr. Thomas Reynolds served as Chief Medical Officer of Seattle Genetics from
March 2007 until his retirement in February 2013. While at Seattle Genetics, he
was responsible for building and leading an integrated clinical development,
regulatory and medical affairs organization, highlighted by the development and
approval of ADCETRIS(R). From 2002 to 2007, Dr. Reynolds served at ZymoGenetics
(acquired by Bristol-Myers Squibb in 2010), most recently as Vice President,
Medical Affairs, where he oversaw the clinical development and regulatory filing
of RECOTHROM(R). Previously, he was Vice President, Clinical Affairs at Targeted
Genetics, and before that he was at Somatix Therapy (acquired by Cell Genesys in
1997). Dr. Reynolds received his M.D. and Ph.D. in Biophysics from Stanford
University and a B.A. in Chemistry from Dartmouth College.


Stem Cell Therapeutics (SCT) also announced that two long-serving directors, Mr.
Dean Peterson and Dr. James DeMesa, have retired from the Board.


"We are appreciative of the strong support and contributions from Dean and James
in the past, particularly in the recent period when we jointly undertook to
transform the company. Dean Peterson was the architect behind the reformation of
the company and helped recruit the board that has undertaken this task. We are
grateful to him and James for their integrity and enthusiasm" remarked SCT's
Chairman, Dr. Calvin Stiller. "The addition of Mr. Beshar and Dr. Reynolds, two
highly accomplished professionals, to the Board provides us with invaluable
skills and expertise in finance and clinical development, areas of critical
importance to our future success. The composition of the current Board reflects
our new strategic goals, our new focus on immunotherapy and oncology, as well as
our new US institutional investor-base and capital markets aspirations."


"We have promising assets, an exceptional management team, a board second to
none, and we are well funded. As I leave the board I have an elevated level of
confidence in our successful pursuit of value creation," commented Mr. Peterson.


The company also announced that the Board of Directors has granted options to
purchase 200,000 common shares of the Corporation to each of the newly appointed
directors. The options were issued at an exercise price of $0.63 per share for a
ten-year term. The grant of options is subject to acceptance by the TSX Venture
Exchange.


About Stem Cell Therapeutics:

Stem Cell Therapeutics Corp. (SCT) is an immuno-oncology company advancing
cancer stem cell discoveries into novel and innovative cancer therapies.
Building on over half a century of leading and groundbreaking Canadian stem cell
research, the company is supported by established links to a group of prominent
Toronto academic research institutes and cancer treatment centers, representing
one of the world's most acclaimed cancer research hubs. The Company has two
premier preclinical programs, SIRPaFc and a CD200 monoclonal antibody (mAb),
which target two key immunoregulatory pathways that tumor cells exploit to evade
the host immune system. SIRPaFc is an antibody-like fusion protein that blocks
the activity of CD47, a molecule that is upregulated on cancer stem cells in AML
and several other tumors. The CD200 mAb is a fully human monoclonal antibody
that blocks the activity of CD200, an immunosuppressive molecule that is
overexpressed by many hematopoietic and solid tumors. SCT's clinical stage
programs include the recently in-licensed program focused on the structure of
tigecycline, which is currently being evaluated in a multi-centre Phase I study
in patients with acute myeloid leukemia (AML), as well as TTI-1612, a non-cancer
stem cell asset that recently completed a 28-patient Phase I trial in
interstitial cystitis ("IC") patients. For more information, visit:
www.stemcellthera.com


Caution Regarding Forward-Looking Information:

This press release may contain forward-looking statements, which reflect SCT's
current expectation regarding future events. These forward-looking statements
involve risks and uncertainties that may cause actual results, events or
developments to be materially different from any future results, events or
developments expressed or implied by such forward-looking statements. Such
factors include changing market conditions; the successful and timely completion
of pre-clinical and clinical studies; the establishment of corporate alliances;
the impact of competitive products and pricing; new product development risks;
uncertainties related to the regulatory approval process or the ability to
obtain drug product in sufficient quantity or at standards acceptable to health
regulatory authorities to complete clinical trials or to meet commercial demand;
and other risks detailed from time to time in SCT's ongoing quarterly and annual
reporting. Except as required by applicable securities laws, SCT undertakes no
obligation to publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Stem Cell Therapeutics Corp.
James Parsons
Chief Financial Officer
+1 416 595 0627
jparsons@stemcellthera.com
www.stemcellthera.com


Investor Contact:
Jeff Ramson/Kirin Smith
ProActive Capital
+1 646-863-6519
jramson@proactivecapital.com
ksmith@proactivecapital.com

Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Mar 2024 to Apr 2024

Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Apr 2023 to Apr 2024